Image
Meet us at AACR24 Booth 3657. Three FNL representatives shown in three separate pictures.

The Frederick National Laboratory is attending the 2024 American Association for Cancer Research (AACR) annual meeting in San Diego. Our team will have a booth in the exhibitor hall to discuss partnership and job opportunities while our scientists will be giving a variety of poster presentations.

Exhibitor booth 3657

Meet representatives of our Partnership Development Office and talent recruiters at our booth in the exhibition hall daily during the conference.

  • Sunday, April 7: 1-5 p.m.
  • Monday, April 8: 9 a.m.-5 p.m.
  • Tuesday, April 9: 9 a.m.-5 p.m.
  • Wednesday, April 10: 9 a.m.-12:30 p.m. 

Exhibitor Spotlight Presentation

1:30-2:30 p.m, Sunday, April 7: Spotlight Theater C - Sails Pavilion

  • Session: A New Era of Discovery Power: From comprehensive microenvironment characterization to multiomic liquid biopsy
  • Presenter: Li Chen, Molecular Characterization Laboratory, Frederick National Laboratory

3:45-4 p.m., Sunday, April 7: Ballroom 20 CD - Upper Level

Scientific posters

Stop by our scientific posters. Scientists who will be at the conference are bolded.

Sunday, April 7

1:30-5 p.m.

Session Title Location Abstract Number FNL Authors
Circulating Nucleic Acids 1 Functional characterization and a real-world clinical laboratory pilot of the Foundation for the National Institutes of Health’s (FNIH) circulating tumor DNA (ctDNA) quality control materials (QCMs) Section 40 978 / 19 Mickey Williams, Chris Karlovich, Thomas Forbes
Pediatric Sarcomas and Other Solid Tumors: Translational Endogenous HiBiT-tagging of PAX3-FOXO1 reveals downregulation of the fusion oncogene by CDK inhibitors and has synergy with vincristine Section 44 1089 / 10 Chris Karlovich & Raj Chari
DNA Damage and Repair 1 PI3K-AKT-mTOR signaling pathways play important roles in chromosomal instability-induced innate immune response in cancer cells Section 17 411 / 11 Pinyi Lu

Monday, April 8

9 a.m.-12:30 p.m.

Session Title Location Abstract Number FNL Authors
Liquid Biopsy and Precision Oncology Impact of delayed processing on cfDNA quantity and quality using STRECK cfDNA tubes: Connect Pilot Study Section 36 2292 / 3 Mickey Williams, Chris Karlovich, Norma Diaz-Mayoral, Heather Cooley, Angela de Palatis, Eric Greenbank
Pharmacodynamic Biomarkers of Drug Response Elucidation of the fates of CDK2 inhibited aneuploid and residual lung cancers Section 30 2117 / 8 Ethan Dmitrovsky, Liliya Tyutyunyk, Xi Liu, Kedar Narayan
Cell Cycle, DNA Repair, and Telomere Biology Exploring the role of a TERT intronic tandem repeat in regulating cell proliferative responses to environmental factors and cancer risk Section 17 1644 / 14 Raj Chari

1:30-5 p.m. 

Session Title Location Abstract Number FNL Authors
Animal Models of Cancer Emergence of frameshift mutations during tumorigenesis in VCMsh2 mouse model of Lynch syndrome Section 6 1445 / 16 Yurong Song, Shaneen Baxter, Brandon Somerville, Chelsea Sanders, Ryan Baugher, Stephanie Mellott, Heidi Lawhorn, Teri Plona, Ligia Pinto
Late-Breaking Research: Tumor Biology 1 Polymerase θ (POLθ) inhibitors (novobiocin, ART-558, RP6685) were tested with 22 approved and investigational agents in multi-cell type spheroids of genetically selected patient-derived human tumor cell lines Section 54 LB215 / 10 Tom Dexheimer, Thomas Silvers, Nathan Coussens
High-Throughput Screening and New Assay Technology Development and performance of the National Cancer Institute’s HTS384 NCI60 screen: A modernized platform to support drug discovery and development by the worldwide cancer research community Section 20 3090 / 1 Nathan Coussens, Tom Dexheimer, Eric Jones, Thomas Silvers, John Britt
First-in-Human Phase I Clinical Trials 1 Phase 1 trial of bortezomib and clofarabine combination in adults with refractory solid tumors Section 48 CT120 / 28 Ralph Parchment, Apurva Srivastava, Deb Wilsker, Brandon Miller, Jeevan Govindharajulu, Will Herrick, Angie Dull, Donna Ketchum, Shaowei Li, Jiuping Ji
Novel Therapeutics KIFC1 inhibition elicits antineoplastic activity in small cell lung cancer by inducing anaphase catastrophe Section 29 3347 / 4 Ethan Dmitrovsky, Xi Liu, Masanori Kawakami

 Tuesday, April 9

9:30 a.m.-12:30 p.m.

Session Title Location Abstract Number FNL Authors
Integrative Computational Approaches 1 / Analytic Pipeline Optimization Computational modeling-based discovery of novel anticancer drug candidates targeting centromere-associated protein E Section 37 4945 / 10 Pinyi Lu, Michael Weil, Naomi Ohashi, Eric Stahlberg
Mechanisms of Drug Resistance and Novel Combinations Combinations of Cdc-like kinase (CLK) inhibitors with targeted oncology agents or standard chemotherapy in patient-derived multi-cell type tumor spheroids Section 25 4608 / 6 Tom Dexheimer, Thomas Silvers, Nathan Coussens
Immune Modulation with Cytokines hetIL-15 and Fenofibrate combination alters the metabolic fitness of tumor-infiltrating CD8+T cells leading to TNBC tumor eradication in mice Section 4 4064 / 8 Sevasti Karaliota and Breana Myers
Characterization of Mutational Processes and Drivers in Cancer Development and Evolution Insight into the structure of breakage fusion bridge events and chromothripsis in cancer cell lines using long-read sequencing Section 15 4334 / 4 Hong Lou
Biomarkers and Molecular Targets for Cancer Prevention Development of self-amplifying RNA vaccines targeting prostate tissue-restricted and tumor-associated antigens Section 31 4778 / 14 Jason Marshall, Lurii Koboziev, Bradley Beckman

1:30-5 p.m.

Session Title Location Abstract Number FNL Authors
Integrative Cancer Science The cancer omics and drug experimental response dataset (CODERData): A harmonized benchmark dataset for machine learning models of drug response prediction Section 36 6210 / 13 Michael Weil
Phase II Clinical Trials 2 Atezolizumab clinical trial biopsies reveal varied immune landscapes in clear cell sarcoma and chondrosarcoma Section 48 CT263 / 22 Katherine Ferry-Galow, Ralph Parchment, Kristin Fino

Wednesday, April 10

9 a.m.-12:30 p.m.

Session Title Location Abstract Number FNL Authors
New Software Tools for Data Analysis Improving FAIRness of computational approaches for cancer: The computational resources for cancer research portal Section 35 7432 / 27 Eric Stahlberg, Lynn Borkin, Ruth Frost, Sara Jones, Amar Khalsa, Lauren Lewis, Sunita Menon

 

2024-04-07 09:00 2024-04-10 17:00 America/New_York Meet us at AACR 2024 The Frederick National Laboratory is attending the 2024 American Association for Cancer Research (AACR) annual meeting in San Diego. Our team will have a booth in the exhibitor hall to discuss partnership and job opportunities while our scientists will be giving a variety of poster presentations. Exhibitor booth 3657 Meet representatives of our Partnership Development Office and talent recruiters at our booth in the exhibition hall daily during the conference. Sunday, April 7: 1-5 p.m. Monday, April 8: 9 a.m.-5 p.m. Tuesday, April 9: 9 a.m.-5 p.m. Wednesday, April 10: 9 a.m.-12:30 p.m ...

San Diego Convention Center , 111 Harbor Dr, San Diego, CA 92101 Frederick National Laboratory